MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
71.10
+0.32 (+0.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close70.78
Open70.91
Bid68.94 x 900
Ask0.00 x 900
Day's Range70.90 - 71.57
52 Week Range52.83 - 71.57
Volume17,033,118
Avg. Volume8,163,103
Market Cap189.093B
Beta1.06
PE Ratio (TTM)146.60
EPS (TTM)0.49
Earnings DateOct 25, 2018
Forward Dividend & Yield1.92 (2.74%)
Ex-Dividend Date2018-09-14
1y Target Est72.15
Trade prices are not sourced from all markets
  • Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
    Zacksyesterday

    Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda

    Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.

  • New Indications Are Expected to Drive Future Growth of Keytruda
    Market Realistyesterday

    New Indications Are Expected to Drive Future Growth of Keytruda

    According to Goldman Sachs analyst Jami Rubin, Merck’s (MRK) Keytruda can earn annual revenues as high as $16.0 billion by 2025. Credit Suisse expects the drug to report peak sales of about $10.0 billion by 2023. According to Trefis estimates, Keytruda is expected to attain peak sales of ~$8.0 billion going forward.

  • Keytruda Is a Major Growth Asset for Merck in 2018
    Market Realistyesterday

    Keytruda Is a Major Growth Asset for Merck in 2018

    In the first half of the year, Keytruda accounted for 15.27% of Merck’s (MRK) total revenues. Keytruda earned more than 40.0% of its total sales from international markets, despite the company having launched the drug only as a monotherapy and not as a combination regimen in these markets. By the end of the first half of the year, Keytruda was earning 60.0%–65.0% of its revenues from sales to lung cancer patients.

  • Why Merck Stock Has Risen 28.2% Year-to-Date
    Market Realistyesterday

    Why Merck Stock Has Risen 28.2% Year-to-Date

    Merck (MRK) stock has risen from $54.93 on January 2 to $70.42 on September 18—a 28.2% increase year-to-date. The performance of Merck stock has been closely related to the sales, clinical trial outcomes, and regulatory decisions for the company’s leading immuno-oncology drug, Keytruda. Approved in 13 indications and eight tumor types, Keytruda reported sales of $1.7 billion in the second quarter.

  • Motley Fool2 days ago

    How Do Drugs Compete Against Each Other?

    Investors can keep an eye on these four factors to tell which drugs will out-compete the rest.

  • Flexible labs, co-working space: Big Pharma is rethinking real estate
    American City Business Journals2 days ago

    Flexible labs, co-working space: Big Pharma is rethinking real estate

    At an industry event Thursday, representatives from both Merck & Co. and Bristol-Myers Squibb stressed the importance of flexibility in real-estate assets.

  • Business Wire2 days ago

    Merck Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO™ (doravirine) in the European Union for the Treatment of HIV-1 Infection

    Merck , known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO™, a once-daily fixed-dose combination tablet of doravirine , lamivudine and tenofovir disoproxil fumarate ; and PIFELTRO™ ...

  • Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
    Zacks2 days ago

    Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

    In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

  • Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
    Market Realist2 days ago

    Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates

    GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • MarketWatch2 days ago

    Galectin stock lifts 15% premarket on early cancer combination trial results

    Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .

  • Merck Publishes Corporate Responsibility Report
    PR Newswire2 days ago

    Merck Publishes Corporate Responsibility Report

    KENILWORTH, N.J., Sept. 20, 2018 /PRNewswire/ -- Merck (MRK), known as MSD outside the United States and Canada, today issued its 2017/2018 global Corporate Responsibility Report. "Our company has an important role to play in tackling some of humanity's greatest challenges," said Kenneth C. Frazier, chairman and chief executive officer, Merck. The report highlights Merck's approach to creating social, environmental and economic value for the company and its stakeholders and the company's commitment to operate ethically and transparently.

  • How Accenture’s Partnership with Merck Could Be Helpful
    Market Realist2 days ago

    How Accenture’s Partnership with Merck Could Be Helpful

    Accenture (ACN) has teamed up with Merck & Co. (MRK), one of the leading pharmaceutical giants outside the United States, to drive production, effectiveness, and innovation in the initial stages of drug development. Both companies have included Amazon’s (AMZN) AWS (Amazon Web Services) cloud computing, The involvement of the leading public cloud service provider should allow MSD to introduce a cloud-based informatics research platform to support the life sciences industry related to drug manufacturing.

  • GuruFocus.com3 days ago

    Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ...

    Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 279,851 shares of MRK on 09/18/2018 at an average price of $70.08 a share.

  • Can Accenture Meet Its Operating Margin Guidance in Q4 2018?
    Market Realist3 days ago

    Can Accenture Meet Its Operating Margin Guidance in Q4 2018?

    Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist3 days ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Accenture, Merck & Amazon AWS Partner for Cloud Platform
    Zacks4 days ago

    Accenture, Merck & Amazon AWS Partner for Cloud Platform

    Accenture's (ACN) latest partnership is likely to boost its Products segment.

  • MarketWatch4 days ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realist4 days ago

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Exploring Pharmaceutical Stocks’ Revenue Growth Rates
    Market Realist4 days ago

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
    Zacks4 days ago

    Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

    Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

  • A Look at the Dividends Paid by Pharma Stocks in 2018
    Market Realist4 days ago

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
    Market Realist4 days ago

    Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio

    In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.

  • A Look at the Market Caps of the Pharma Stocks under Review
    Market Realist5 days ago

    A Look at the Market Caps of the Pharma Stocks under Review

    As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.

  • How Pharmaceutical ETFs Have Performed in 2018
    Market Realist5 days ago

    How Pharmaceutical ETFs Have Performed in 2018

    Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.

  • Lenvima Could Significantly Boost Merck’s Revenue Growth
    Market Realist5 days ago

    Lenvima Could Significantly Boost Merck’s Revenue Growth

    In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.